GO:0001758 retinal dehydrogenase (NAD+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001758 (retinal dehydrogenase (NAD+) activity) catalyzes the NAD+-dependent oxidation of retinal to retinoate, acting on both 11-trans and 13-cis retinal.
• The reaction is a key step in retinoic acid biosynthesis, linking vitamin A metabolism to gene regulation and cell differentiation.
• Retinal dehydrogenase activity is elevated by xenobiotics such as phenobarbital and ethanol, indicating inducible regulation.
• Structural studies of retinal dehydrogenase type II reveal a conserved NAD+-binding Rossmann fold and a substrate channel that confers retinal specificity.
• Altered retinal dehydrogenase activity and NAD-redox imbalance are implicated in diabetic retinopathy and other retinal pathologies.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of GO:0001758 in development, cancer, and neurodegeneration [3,6].
Description
Retinal dehydrogenase (NAD+) activity, encoded by GO:0001758, is a molecular function that catalyzes the oxidation of retinal to retinoate using NAD+ as the electron acceptor. This reaction is a critical node in the retinoic acid biosynthetic pathway, converting vitamin A-derived retinaldehyde into the active morphogen retinoic acid, which regulates gene expression, cell differentiation, and embryonic patterning. Because retinoic acid signaling is essential for vision, immunity, and tissue homeostasis, the enzymes carrying this activity are of broad biomedical interest [6,8]. The activity acts on both the 11-trans and 13-cis isomers of retinal, underscoring its role in isomer-specific retinoid metabolism. Researchers study GO:0001758 to understand how retinoid flux is controlled and how its dysregulation contributes to disease [2,8]. The enzyme has been structurally characterized, revealing a conserved NAD+-binding domain and a hydrophobic substrate pocket that determines retinal specificity. In this article, we integrate the QuickGO definition with verified literature to outline the mechanism, key genes, disease links, and CRISPR-based research strategies for GO:0001758.
retinal dehydrogenase (NAD+) activity At A Glance
| GO ID | GO:0001758 |
|---|---|
| GO term | retinal dehydrogenase (NAD+) activity |
| Ontology | molecular_function |
| Synonym | cytosolic retinal dehydrogenase activity; retinal dehydrogenase activity; retinal:NAD+ oxidoreductase activity |
| Major function | NAD+-dependent oxidation of retinal to retinoate (retinoic acid) |
| Substrates | 11-trans-retinal and 13-cis-retinal |
| Cofactor | NAD+ |
| Products | retinoate and NADH |
| Enzyme family | Aldehyde dehydrogenase (ALDH) superfamily |
What Is GO:0001758?
GO:0001758 describes the catalysis of the reaction: retinal + NAD+ + H2O = retinoate + NADH. The enzyme accepts both 11-trans and 13-cis forms of retinal as substrates, using NAD+ as the cofactor and producing retinoate (retinoic acid) and NADH. This activity is synonymous with cytosolic retinal dehydrogenase activity, retinal dehydrogenase activity, and retinal:NAD+ oxidoreductase activity. It belongs to the aldehyde dehydrogenase (ALDH) superfamily, whose members share a conserved catalytic mechanism involving a cysteine nucleophile and an NAD(P)+ cofactor [6,7].
Why Is retinal dehydrogenase (NAD+) activity Important in Cell Biology?
GO:0001758 is essential because it produces retinoic acid, a potent signaling molecule that controls gene expression programs in development, vision, and immunity. Dysregulated retinal dehydrogenase activity alters retinoic acid levels, which can disrupt cell differentiation and contribute to cancer, metabolic disease, and retinal degeneration [3,6,8]. The activity is also inducible by drugs and alcohol, linking environmental exposures to retinoid imbalance. Understanding this activity at the molecular level informs therapeutic strategies targeting ALDH enzymes in oncology and ophthalmology [3,8].
• Produces retinoic acid, a key regulator of embryonic patterning and organogenesis.
• Maintains visual cycle homeostasis by controlling retinal flux in the retina.
• Inducible by phenobarbital and ethanol, linking xenobiotic exposure to retinoid metabolism.
• ALDH1A family members carrying this activity are stem cell markers and cancer therapeutic targets [3,6].
• NAD-redox imbalance involving retinal dehydrogenase contributes to diabetic retinopathy pathogenesis.
• Structural knowledge of retinal dehydrogenase type II guides inhibitor design.
• Genetic variants in retinoid pathway genes affect disease susceptibility and treatment response.
• CRISPR models enable causal testing of GO:0001758 in development and disease [3,6].
Molecular Mechanism of retinal dehydrogenase (NAD+) activity
Substrate binding and isomer recognition
In simple terms: The enzyme grabs retinal and holds it in place so it can be converted to retinoic acid.
Retinal dehydrogenase binds retinal within a hydrophobic substrate channel that accommodates both 11-trans and 13-cis isomers. Structural analysis of retinal dehydrogenase type II at 2.7 A resolution revealed a narrow entrance and a conserved tryptophan residue that positions the aldehyde group near the catalytic cysteine. This architecture ensures specificity for retinal over other aldehydes, a property critical for retinoic acid biosynthesis.
NAD+ cofactor binding and hydride transfer
In simple terms: NAD+ acts as a helper that accepts electrons from retinal, turning it into retinoic acid.
The enzyme uses NAD+ as an electron acceptor, binding it in a Rossmann-fold domain characteristic of the aldehyde dehydrogenase superfamily. Catalysis proceeds via nucleophilic attack by a conserved cysteine on the retinal aldehyde, forming a thiohemiacetal intermediate, followed by hydride transfer to NAD+ to yield NADH. The reaction also requires water, which hydrolyzes the acyl-enzyme intermediate to release retinoate.
Catalytic cycle and product release
In simple terms: After the reaction, the enzyme releases retinoic acid and NADH so it can start again.
Following hydride transfer, the thioester intermediate is hydrolyzed by water, releasing retinoate and regenerating the free cysteine. NADH dissociates from the active site, allowing a new NAD+ molecule to bind and initiate another catalytic cycle. The overall reaction is: retinal + NAD+ + H2O = retinoate + NADH, as defined by GO:0001758.
Regulation by xenobiotics and cellular redox
In simple terms: Certain drugs and alcohol can boost or disrupt this enzyme's activity.
Hepatic retinal dehydrogenase activity is increased after administration of phenobarbital and ethanol, indicating that enzyme levels or specific activity are inducible by xenobiotic exposure. In the retina, diabetes-induced changes in NAD-redox status modulate retinal dehydrogenase function, linking cellular redox balance to enzyme activity. These regulatory mechanisms influence retinoic acid availability and downstream signaling [2,8].
Isoform diversity and tissue distribution
In simple terms: Different versions of the enzyme exist in different tissues, each with specialized roles.
Multiple aldehyde dehydrogenase isoforms, including ALDH1A1, ALDH1A2, and ALDH1A3, exhibit retinal dehydrogenase activity and are expressed in distinct tissue patterns [3,6]. ALDH1A1 is a marker of stem cells and is frequently overexpressed in cancers, where it contributes to retinoic acid synthesis and therapy resistance [3,6]. Retinal dehydrogenase type II is a cytosolic isoform with high specificity for retinal, highlighting functional specialization among family members.
Key Genes Involved in GO:0001758 retinal dehydrogenase (NAD+) activity
The following genes encode enzymes or regulators associated with retinal dehydrogenase (NAD+) activity and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALDH1A1 | Retinal dehydrogenase activity; retinoic acid synthesis | Stem cell marker and cancer target [3,6] |
| ALDH1A2 | Retinal dehydrogenase activity in embryonic development | Retinoic acid signaling in patterning |
| ALDH1A3 | Retinal dehydrogenase activity in neural and cancer cells | Tumor heterogeneity and therapy resistance |
| ALDH1B1 | Aldehyde dehydrogenase family member | Retinoid and xenobiotic metabolism |
| ALDH2 | Mitochondrial aldehyde dehydrogenase | Ethanol metabolism and retinal oxidation |
| RDH10 | Retinol dehydrogenase upstream of retinal dehydrogenase | Retinoic acid biosynthesis |
| RDH11 | Retinol dehydrogenase in visual cycle | Retinal homeostasis |
| CRABP1 | Cellular retinoic acid binding protein | Retinoic acid transport and signaling |
| CRABP2 | Cellular retinoic acid binding protein | Nuclear retinoic acid delivery |
| RARA | Retinoic acid receptor alpha | Downstream effector of retinoic acid |
| RARB | Retinoic acid receptor beta | Gene regulation by retinoic acid |
| RXRA | Retinoid X receptor alpha | Heterodimer partner for RARs |
| CYP26A1 | Retinoic acid degradation enzyme | Controls retinoic acid levels |
| NQO1 | NAD(P)H quinone oxidoreductase | Modifies redox state affecting retinoid metabolism |
| IDH3B | Isocitrate dehydrogenase 3 beta | NAD+ regeneration in retina |
| SDR16C5 | Retinol dehydrogenase | Retinal production for dehydrogenase |
| BCO1 | Beta-carotene oxygenase | Provitamin A conversion to retinal |
| LRAT | Lecithin retinol acyltransferase | Retinyl ester synthesis in visual cycle |
How Is retinal dehydrogenase (NAD+) activity Regulated?
Retinal dehydrogenase (NAD+) activity is regulated at multiple levels. Xenobiotic exposure, such as phenobarbital and ethanol administration, increases hepatic retinal dehydrogenase activity, suggesting transcriptional or post-translational induction. Cellular NAD-redox status modulates enzyme function, as diabetes-induced changes in retinal NAD-redox balance affect retinal dehydrogenase activity. Additionally, the availability of retinal substrate, controlled by upstream retinol dehydrogenases and isomerohydrolases, indirectly regulates flux through this step. Retinoic acid levels are further controlled by CYP26 enzymes that degrade retinoic acid, providing feedback regulation.
retinal dehydrogenase (NAD+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALDH1A1 | Breast cancer stemness and therapy resistance | Knockout and overexpression in breast cancer cell lines |
| ALDH1A3 | Tumor heterogeneity and ALDH1A-specific inhibition | Point mutation of catalytic cysteine in cancer cells |
| NQO1 | Leber hereditary optic neuropathy treatment response | Knock-in of NQO1 variants in retinal cells |
| IDH3B | Retinal NAD+ regeneration and spermiogenesis | Knockout mouse model for retinal viability |
| RDH11 | Visual cycle and retinal homeostasis | Knockout in retinal pigment epithelium cells |
Cancer and stem cell biology
ALDH1A1 and ALDH1A3, which exhibit retinal dehydrogenase activity, are overexpressed in various cancers and mark stem-like cells that drive tumor initiation and therapy resistance [3,6]. Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors, highlighting the clinical relevance of this activity. Targeting retinal dehydrogenase activity may reduce retinoic acid production and impair cancer stem cell maintenance [3,6].
Retinal degeneration and diabetic retinopathy
Diabetes-induced changes in retinal NAD-redox status alter retinal dehydrogenase function and contribute to the pathogenesis of diabetic retinopathy. Proper regulation of retinal dehydrogenase activity is essential for maintaining the visual cycle and retinal viability [5,8]. Disruption of NAD+ regeneration by IDH3B loss does not impair retinal viability, indicating metabolic flexibility, but redox imbalance can still affect retinoid metabolism.
Leber hereditary optic neuropathy and genetic modifiers
Genetic variants affecting NQO1 protein levels, which influence cellular redox and potentially retinoid metabolism, impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy. This illustrates how modifiers of NAD(P)H-dependent pathways can affect retinal disease outcomes.
Nonsyndromic retinitis pigmentosa
Nonsyndromic retinitis pigmentosa is a genetically heterogeneous retinal degeneration that can involve defects in retinoid cycle enzymes, including those upstream and downstream of retinal dehydrogenase. Although direct mutations in GO:0001758 enzymes are not the primary cause, the pathway is critical for photoreceptor health [1,8].
From retinal dehydrogenase (NAD+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALDH1A1 reduce retinoic acid production? | ALDH1A1 knockout cell line [3,6] |
| Does a catalytic cysteine mutation abolish retinal dehydrogenase activity? | Point mutation knock-in of ALDH1A1 C302A |
| Can tagged ALDH1A2 be used to track subcellular localization? | Knock-in of fluorescent tag at endogenous locus |
| Does overexpression of ALDH1A3 increase cancer stem cell traits? | Overexpression in breast cancer cells |
| Does NQO1 variant affect idebenone response? | Knock-in of NQO1 variants in retinal cells |
| Does IDH3B loss alter retinal NAD+ levels? | IDH3B knockout mouse |
How to Study the retinal dehydrogenase (NAD+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH absorbance assay | Retinal dehydrogenase enzymatic activity | Kinetic analysis of purified enzyme [2,7] |
| X-ray crystallography | Three-dimensional structure of enzyme-substrate complex | Substrate specificity and inhibitor design |
| RNA-seq | Transcript levels of ALDH genes | Expression profiling across tissues [3,6] |
| Proteomics | Protein abundance of ALDH isoforms | Validation of expression changes |
| CRISPR knockout screening | Gene essentiality and pathway redundancy | Identification of required isoforms [3,6] |
| Retinoic acid reporter assay | Downstream retinoic acid signaling | Functional readout of enzyme activity |
| NAD+/NADH ratio measurement | Cellular redox status | Linking metabolism to enzyme function |
Enzymatic activity assays
Retinal dehydrogenase activity can be measured spectrophotometrically by monitoring NADH production at 340 nm using retinal as substrate [2,7]. This assay allows kinetic characterization of purified enzymes or cell lysates and is used to assess the effect of mutations or inhibitors.
Structural biology
X-ray crystallography of retinal dehydrogenase type II at 2.7 A resolution revealed the substrate binding pocket and NAD+ coordination, providing a template for understanding retinal specificity. Such structural data guide the design of isoform-specific inhibitors.
Gene expression and proteomics
RNA-seq and quantitative proteomics can quantify ALDH1A family expression across tissues and conditions, revealing regulation by xenobiotics or disease states [2,3]. These methods help identify which isoforms contribute to total retinal dehydrogenase activity in a given context.
CRISPR screening and functional genomics
Pooled CRISPR knockout screens targeting ALDH genes can identify which isoforms are required for retinoic acid production and cell survival [3,6]. Such screens are powerful for dissecting redundant functions among ALDH1A1, ALDH1A2, and ALDH1A3.
How CRISPR Can Be Used to Study GO:0001758 retinal dehydrogenase (NAD+) activity
Knockout
CRISPR knockout of ALDH1A1, ALDH1A2, or ALDH1A3 can abolish specific retinal dehydrogenase activities, enabling researchers to determine which isoform is responsible for retinoic acid production in a given cell type [3,6]. Knockout models also reveal compensatory upregulation among family members.
Point Mutation
Introducing point mutations in the catalytic cysteine or NAD+-binding residues of ALDH1A enzymes via CRISPR base editing or homology-directed repair can dissect the enzymatic mechanism and separate catalytic activity from non-enzymatic functions. Such models are valuable for testing isoform-specific inhibitors.
Knock-in
Knock-in of epitope tags or fluorescent proteins at endogenous ALDH1A loci allows real-time tracking of enzyme localization and dynamics without overexpression artifacts. Knock-in of disease-associated variants, such as NQO1 polymorphisms, can model personalized drug responses.
Overexpression
CRISPR activation or lentiviral overexpression of ALDH1A genes increases retinal dehydrogenase activity and retinoic acid levels, mimicking the overexpression observed in cancer stem cells [3,6]. These models help establish causality between enzyme levels and phenotypes such as differentiation blockade or chemoresistance.
How EDITGENE Supports retinal dehydrogenase (NAD+) activity Research
Researchers studying retinal dehydrogenase (NAD+) activity-related genes often need to determine whether a candidate gene is causally involved in retinoic acid production, retinal homeostasis, or cancer stemness. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of GO:0001758 and its associated genes.
Contact EDITGENE today to design your custom CRISPR model for retinal dehydrogenase (NAD+) activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AKR1C3 Knockout HEK293 Cell Line | EDJ-KQ1964 | Human | 8644 | Details Get a Quote |
| ALDH1A1 Knockout HEK293 Cell Line | EDJ-KQ2024 | Human | 216 | Details Get a Quote |
| ALDH1A3 Knockout HEK293 Cell Line | EDJ-KQ4033 | Human | 220 | Details Get a Quote |
| ALDH1B1 Knockout HEK293 Cell Line | EDJ-KQ4035 | Human | 219 | Details Get a Quote |
| AKR1B1 Knockout HEK293 Cell Line | EDJ-KQ4040 | Human | 231 | Details Get a Quote |
| AKR1C4 Knockout HEK293 Cell Line | EDJ-KQ4264 | Human | 1109 | Details Get a Quote |
| ALDH1A2 Knockout HEK293 Cell Line | EDJ-KQ6383 | Human | 8854 | Details Get a Quote |
| AKR1B10 Knockout HEK293 Cell Line | EDJ-KQ12322 | Human | 57016 | Details Get a Quote |
| ALDH2 Knockout HEK293 Cell Line | EDJ-KQ12328 | Human | 217 | Details Get a Quote |
| ALDH8A1 Knockout HEK293 Cell Line | EDJ-KQ12329 | Human | 64577 | Details Get a Quote |
| HSD17B13 Knockout HEK293 Cell Line | EDJ-KQ17880 | Human | 345275 | Details Get a Quote |
| AKR1C3 Knockout A-549 Cell Line | EDJ-KQ21929 | Human | 8644 | Details Get a Quote |
| AKR1C3 Knockout HCT 116 Cell Line | EDJ-KQ21930 | Human | 8644 | Details Get a Quote |
| AKR1C3 Knockout HeLa Cell Line | EDJ-KQ21931 | Human | 8644 | Details Get a Quote |
| ALDH1A1 Knockout A-549 Cell Line | EDJ-KQ22054 | Human | 216 | Details Get a Quote |
Displaying Records 1 To 15 Of 47 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About retinal dehydrogenase (NAD+) activity
What is retinal dehydrogenase (NAD+) activity?
It is the enzymatic activity defined by GO:0001758 that catalyzes the NAD+-dependent oxidation of retinal to retinoate, acting on both 11-trans and 13-cis retinal.
What genes are involved in retinal dehydrogenase (NAD+) activity?
Key genes include ALDH1A1, ALDH1A2, and ALDH1A3, which encode aldehyde dehydrogenases with retinal dehydrogenase activity [3,6].
What is the reaction catalyzed by GO:0001758?
The reaction is: retinal + NAD+ + H2O = retinoate + NADH, as defined by QuickGO.
How is retinal dehydrogenase activity measured?
It is commonly measured by monitoring NADH production at 340 nm using retinal as substrate in spectrophotometric assays [2,7].
What diseases are associated with retinal dehydrogenase dysfunction?
Dysregulation is linked to cancer stemness, diabetic retinopathy, and retinal degenerations such as retinitis pigmentosa [1,3,8].
Can retinal dehydrogenase activity be induced?
Yes, hepatic retinal dehydrogenase activity increases after phenobarbital and ethanol administration.
What is the structure of retinal dehydrogenase type II?
It has a conserved NAD+-binding Rossmann fold and a hydrophobic substrate channel that confers retinal specificity, as revealed by X-ray crystallography at 2.7 A.
How does NAD+ redox status affect retinal dehydrogenase?
Diabetes-induced changes in retinal NAD-redox status modulate retinal dehydrogenase activity, implicating redox balance in diabetic retinopathy.
What CRISPR models are available for studying GO:0001758?
Knockout, point mutation, knock-in, and overexpression models of ALDH1A genes can be generated to dissect function [3,6].
Why is retinoic acid production important?
Retinoic acid is a signaling molecule that regulates gene expression, cell differentiation, and embryonic development.
Conclusion
GO:0001758, retinal dehydrogenase (NAD+) activity, is a central enzymatic function in retinoic acid biosynthesis with broad implications for development, cancer, and retinal health [6,8]. Its mechanism involves NAD+-dependent oxidation of retinal isomers, and its dysregulation contributes to diseases such as cancer and diabetic retinopathy [3,7,8]. CRISPR-based models provide powerful tools to dissect the causal roles of ALDH1A isoforms and to develop targeted therapies [3,6]. EDITGENE offers comprehensive services to support these research efforts.
References
- 1. Adam MP et al.. 1993. Nonsyndromic Retinitis Pigmentosa Overview.. PMID: 20301590
- 2. Leo MA et al.. 1989. Increased hepatic retinal dehydrogenase activity after phenobarbital and ethanol administration.. Biochem Pharmacol 38(1):97-103 PMID: 2910311
- 3. Pequerul R et al.. 2025. Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors.. Cell Chem Biol 32(10):1260-1278.e12 PMID: 41033308
- 4. Aleo SJ et al.. 2024. Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy.. Cell Rep Med 5(2):101383 PMID: 38272025
- 5. Zhu S et al.. 2022. Isocitrate dehydrogenase 3b is required for spermiogenesis but dispensable for retinal viability.. J Biol Chem 298(9):102387 PMID: 35985423
- 6. Tomita H et al.. 2016. Aldehyde dehydrogenase 1A1 in stem cells and cancer.. Oncotarget 7(10):11018-32 PMID: 26783961
- 7. Lamb AL et al.. 1999. The structure of retinal dehydrogenase type II at 2.7 A resolution: implications for retinal specificity.. Biochemistry 38(19):6003-11 PMID: 10320326
- 8. Obrosova IG et al.. 2001. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy.. Pharmacology 62(3):172-80 PMID: 11287819
